Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
Public ClinicalTrials.gov record NCT00850239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to demonstrate the efficacy of dutogliptin over 26 weeks (as evidenced by placebo-corrected changes in HbA1c relative to baseline), to demonstrate safety and tolerability of dutogliptin, and to demonstrate changes in fasting plasma glucose over 26 weeks.
Study identification
- NCT ID
- NCT00850239
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 700 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2009 (Type not available)
- Primary completion
- Oct 2010 (Estimated)
- Completion
- Dec 2010 (Estimated)
- Last update posted
- Aug 11, 2010
2009 – 2010
United States locations
- U.S. sites
- 34
- U.S. states
- 19
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phenomix Investigational Site 115 | Montgomery | Alabama | — | — |
| Phenomix Investigational Site 121 | Tempe | Arizona | — | — |
| Phenomix Investigational Site 137 | Tempe | Arizona | — | — |
| Phenomix Investigational Site 105 | Anaheim | California | — | — |
| Phenomix Investigational Site 123 | Chico | California | — | — |
| Phenomix Investigational Site 134 | Escondido | California | — | — |
| Phenomix Investigational Site 103 | Long Beach | California | — | — |
| Phenomix Investigational Site 106 | Los Angeles | California | — | — |
| Phenomix Investigational Site 143 | Coral Gables | Florida | — | — |
| Phenomix Investigational Site 142 | Hialeah | Florida | — | — |
| Phenomix Investigational Site 119 | Jacksonville | Florida | — | — |
| Phenomix Investigational Site 133 | Kissimmee | Florida | — | — |
| Phenomix Investigational Site 141 | Dunwoody | Georgia | — | — |
| Phenomix Investigational Site 101 | Honolulu | Hawaii | — | — |
| Phenomix Investigational Site 135 | Chicago | Illinois | — | — |
| Phenomix Investigational Site 124 | Indianapolis | Indiana | — | — |
| Phenomix Investigational Site 127 | Indianapolis | Indiana | — | — |
| Phenomix Investigational Site 136 | Brockton | Massachusetts | — | — |
| Phenomix Investigational Site 125 | Kalamazoo | Michigan | — | — |
| Phenomix Investigational Site 138 | Biloxi | Mississippi | — | — |
| Phenomix Investigational Site 122 | Las Vegas | Nevada | — | — |
| Phenomix Investigational Site 140 | Las Vegas | Nevada | — | — |
| Phenomix Investigational Site 131 | Brick | New Jersey | — | — |
| Phenomix Investigational Site 110 | Trenton | New Jersey | — | — |
| Phenomix Investigational Site 116 | Albuquerque | New Mexico | — | — |
| Phenomix Investigational Site 107 | Winston-Salem | North Carolina | — | — |
| Phenomix Investigational Site 130 | Cincinnati | Ohio | — | — |
| Phenomix Investigational Site 118 | Cuyahoga Falls | Ohio | — | — |
| Phenomix Investigational Site 112 | Greenville | South Carolina | — | — |
| Phenomix Investigational Site 102 | Dallas | Texas | — | — |
| Phenomix Investigational Site 139 | Dallas | Texas | — | — |
| Phenomix Investigational Site 126 | El Paso | Texas | — | — |
| Phenomix Investigational Site 104 | San Antonio | Texas | — | — |
| Phenomix Investigational Site 100 | Kenosha | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00850239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 11, 2010 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00850239 live on ClinicalTrials.gov.